The disease was writing itself in blood, and we didn't know how to read it.
Blood proteins like TAU-217 can now reveal brain pathology years before clinical symptoms, transforming dementia diagnosis from complex imaging to simple blood tests. Multiple neurodegenerative diseases share common inflammatory and immune mechanisms despite different protein aggregations, suggesting unified therapeutic approaches may be possible.
- TAU-217, a brain-specific protein, can now be measured in blood to detect Alzheimer's years before symptoms
- Carlos Cruchaga leads the Neurogenomics and Informatics group at Washington University in St. Louis
- Pathological changes in neurodegenerative diseases begin 15-20 years before clinical symptoms appear
- Multiple dementias share common inflammatory and immune mechanisms despite different protein signatures
Renowned geneticist Carlos Cruchaga discusses breakthrough blood biomarkers that can detect Alzheimer's and other neurodegenerative diseases before symptoms appear, enabling earlier treatment and monitoring.
Carlos Cruchaga finished his doctoral thesis in genetics the same year the human genome was first sequenced. It was the early 2000s, and he noticed something that would shape his career: there was almost nothing known about how to treat neurodegenerative disease, almost no framework for understanding it. He became obsessed with mapping the architecture of that ignorance. Now, as the leader of the Neurogenomics and Informatics group at Washington University in St. Louis, he spends his days trying to decode why proteins misbehave in the brain—why they clump together, why they stay clumped, and what happens next.
Alzheimer's and Parkinson's are the diseases most people know by name, but there are others: frontotemporal dementia, Lewy body dementia. What they share is a pattern of protein aggregation, though the proteins themselves differ. In Alzheimer's, it's amyloid-beta and tau. In Parkinson's, alpha-synuclein. Cruchaga's laboratory uses molecular data—proteins, metabolites, genes—to trace the chain of events that leads to aggregation, and then to trace what happens after. The puzzle is this: proteins begin clumping in the brain years, sometimes decades, before a person shows any symptoms. Yet protein aggregation alone doesn't predict how fast dementia will progress. Something else is happening. Something that keeps the neurodegeneration moving forward even after the proteins have settled. That's what his team is hunting for.
What they've found is messier and more interesting than expected. Yes, each disease has its signature proteins. But many people carry the pathological hallmarks of multiple diseases at once. Someone with Alzheimer's might also have Parkinson's-type protein deposits. The diseases bleed into each other. When Cruchaga's lab examined blood and cerebrospinal fluid samples using advanced protein analysis, they discovered that many proteins are dysregulated across all these conditions—far more than anyone had anticipated. But the most striking finding was this: many of the same proteins are altered in every disease. And they're not random proteins. They're involved in immune function and inflammation. The diseases, it seems, share a common mechanism underneath their different surfaces.
The origins remain elusive. These are complex diseases with many moving parts. Genetic factors play a role—variants that predispose someone to higher risk, often related to immune response or to the lysosome, the cellular machinery that clears away aggregated proteins. Environmental factors matter too: diet, anything that triggers inflammation or amplifies immune response. But the timeline is long. Pathological changes begin fifteen to twenty years before symptoms appear, sometimes longer. It's not a switch that flips. It's a slow accumulation.
Five years ago, the scientific community believed blood biomarkers for these diseases were a distant dream. The brain seemed sealed off, independent, too important to leak its secrets into the bloodstream. That assumption has collapsed. A protein called TAU-217, produced exclusively in the brain, can now be measured in blood. When it appears there, it reveals what's happening in the brain itself. This single discovery illustrates how far the field has moved. Other biomarkers are being identified for Parkinson's, frontotemporal dementia, Lewy body disease. The technology to detect them is finally catching up to the biology.
The practical implications are immediate. Dementia is notoriously hard to diagnose—distinguishing one type from another requires imaging, cognitive testing, sometimes years of uncertainty. A blood test changes that. It also changes treatment. New therapies for Alzheimer's now exist, drugs that clear amyloid-beta from the brain. If patients are identified earlier, treatment can begin earlier, before irreversible damage accumulates. The same biomarkers that enable diagnosis can monitor treatment effectiveness. As amyloid-beta is cleared, TAU-217 levels drop. The biology speaks. Doctors can see, in real time, whether the drug is working.
Alzheimer's research is ahead of the curve. But the other dementias are catching up. What Cruchaga and others are building is a new diagnostic paradigm: simple, objective, early. Not a guess based on symptoms that have already stolen years. Not a scan that shows damage already done. A blood test that whispers what the brain is becoming, before the person knows anything is wrong.
Citas Notables
Five years ago, the scientific community believed blood biomarkers for these diseases were a distant dream. That assumption has collapsed.— Carlos Cruchaga, geneticist and neurodegenerative disease researcher
These diseases are characterized by protein aggregation in the brain and by inflammation and immune response as a mechanism common to all of them.— Carlos Cruchaga, on shared pathways across different dementias
La Conversación del Hearth Otra perspectiva de la historia
When you say the brain was thought to be sealed off, what did that assumption cost us?
Time, mostly. We were looking for answers in the wrong places—imaging, cognitive tests, things that only light up after damage is visible. Meanwhile, the disease was already writing itself in the blood, and we didn't know how to read it.
But now you can read it. Does that mean we can stop these diseases?
Not yet. We can catch them earlier, start treatment sooner. That's not nothing. But stopping them entirely—that requires understanding why the proteins aggregate in the first place. We're getting closer to that answer.
You mentioned that different diseases share inflammatory mechanisms. Does that mean one drug could treat multiple dementias?
That's the hope, yes. If inflammation is the common thread, then maybe we're not chasing five different diseases. Maybe we're chasing one disease wearing different masks.
How early can you detect these changes now?
With TAU-217, we can see Alzheimer's pathology years before symptoms. The exact timeline depends on the person—genetics, environment, how fast their particular biology is moving. But we're talking about a window of opportunity that didn't exist before.
What happens to someone who tests positive but has no symptoms?
That's the question we're learning to answer. Do you treat them? When? How aggressively? These are clinical questions now, not just scientific ones. The biomarkers give us the information. The hard part is knowing what to do with it.
And if the treatment works—if you clear the amyloid and the tau drops—does that mean the person won't develop dementia?
We don't know yet. That's what the trials are trying to show. But the logic is sound: if you remove the pathology before symptoms appear, you might prevent them from appearing at all.